The Centers for Medicare & Medicaid Services Friday finalized policy and technical changes to the Medicare Advantage and prescription drug benefit for contract year 2023. To improve MA plan oversight, the final rule would reinstate plan reporting on medical loss ratio requirements that were relaxed in 2017; require plans to demonstrate a sufficient provider network when applying for a new or expanded contract; strengthen CMS’s ability to evaluate plan performance when reviewing proposals for new or expanded contracts; require plans to provide certain materials to beneficiaries in culturally and linguistically appropriate ways; and strengthen oversight of third-party marketing organizations, among other consumer protection provisions. The rule also codifies provisions intended to improve and better assess quality for special needs plans that serve beneficiaries dually eligible for Medicare and Medicaid. 

Related News Articles

Blog
After two years on the front lines in the battle against this pandemic, hospitals and health systems have seen a dramatic rise in costs of labor, drugs,…
Headline
The AHA today urged the Centers for Medicare & Medicaid Services to “take swift action to hold Medicare Advantage plans accountable for inappropriately and…
Headline
Last year, 42% of all Medicare beneficiaries received benefits through private Medicare Advantage plans, with enrollment in these plans growing by nearly 10%…
Headline
The Centers for Medicare & Medicaid Services should take steps to prevent Medicare Advantage organizations from denying coverage and payment for medically…
Headline
The Centers for Medicare & Medicaid Services yesterday finalized certain changes to Medicare Advantage maximum out-of-pocket and cost sharing limits for…
Headline
The Centers for Medicare & Medicaid Services yesterday announced final updates and changes to its Medicare Advantage and Part D payment methodologies for…